Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 83

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 83
---
 of the above adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB’s ASC Topic 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes. The table below contains ranges of assumptions used in the valuation of outstanding equity awards for the relevant fiscal years. For more information, please see the notes to our financial statements in our Annual Report on Form 10-K and the footnotes to the Summary Compensation Table of this Proxy Statement.**

| Assumptions             | ​ | ​ | As of the MeasurementDates in Fiscal Year 2024 | ​ |
| Expiration term (years) | ​ | ​ | 2.16–9.85                                      | ​ |
| Strike price            | ​ | ​ | $16.00– $70.93                                 | ​ |
| Volatility              | ​ | ​ | 70.67% –87.18%                                 | ​ |
| Expected dividend yield | ​ | ​ | 0.0% –0.0%                                     | ​ |
| Risk-free interest rate | ​ | ​ | 3.70% –4.62%                                   | ​ |

(4) For the relevant fiscal year, represents the cumulative total shareholder return (“ TSR ”) of our common stock and the NASDAQ Biotechnology Index at the end of each fiscal year. In each case, assume reinvestment of dividends and an initial investment of $100 on December 31, 2020. (5) The dollar amounts reported represent the net loss reflected in the Company’s audited financial statements for the applicable year. Narrative to Pay Versus Performance Table Analysis of the Information Presented in the Pay Versus Performance Table As described in more detail above in “Compensation Discussion and Analysis” in this Proxy Statement, the Company’s executive compensation program reflects a performance-driven compensation philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, those Company measures are not financial performance measures and are therefore not presented in the Pay Versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with CAP (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year.

57

TABLE OF CONTENTS Required Disclosure of the Relationship Between CAP and Financial Performance In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions